Cellyan Biotechnology
HKPD
4 hedge funds and large institutions have $35.5K invested in Cellyan Biotechnology in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0.1% less ownership
Funds ownership: 0.67% → 0.57% (-0.1%)
42% less capital invested
Capital invested by funds: $60.7K → $35.5K (-$25.2K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$4.31K |
| 2 |
SG
StoneX Group
New York
|
-$2.83K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SG
1
StoneX Group
New York
| $22.4K | -$2.83K | -3,889 | -9% |
|
|
CS
2
Clear Street
New York
| $6.83K | – | – | – |
|
|
3
Two Sigma Investments
New York
| $6.16K | -$4.31K | -5,919 | -35% |
|
|
4
UBS Group
Zurich,
Switzerland
| $63 | -$1.04K | -1,426 | -93% |
|
HKPD Hedge Fund Activity: Q1 2026 in Review
4 of the 8,132 institutional investors tracked by Wall St. Rank reported a position in Cellyan Biotechnology (HKPD) for Q1 2026, worth a combined $35.5K — down 42% from $60.7K a quarter earlier.
Fund positioning in HKPD was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was Two Sigma Investments, cutting an estimated $4.31K.
- 4 institutional investors held Cellyan Biotechnology (HKPD) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $35.5K of Cellyan Biotechnology stock for Q1 2026, down 42% quarter-over-quarter.
- 0 funds opened new Cellyan Biotechnology positions in Q1 2026 and 0 closed out.
- The largest Cellyan Biotechnology seller in Q1 2026 was Two Sigma Investments, an estimated $4.31K sold.
Based on aggregated 13F filings for Q1 2026.